Search This Blog

Thursday, January 6, 2022

Avalo ends multiple myeloma program

 

  • AVTX-007 data in multiple myeloma indicated the therapy is generally safe and well tolerated; no efficacy signal was seen at the high dose and the decision was made to discontinue the program

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)